

AMENDMENTS TO THE CLAIMS

F 4
1. (currently amended) ~~An recombinant~~ antibody ~~product~~, comprising the V_H domain of the antibody produced by the hybridoma of ATCC deposit number CRL 8001, wherein the cysteine at position H100A of said V_H domain is substituted with a polar amino acid, wherein said position H100A is according to the Kabat numbering system, wherein said ~~recombinant~~ antibody ~~product~~ comprises the amino acid sequence depicted by SEQ ID NO:2.

Claims 2-3 (cancelled).

F 5
4. (currently amended) A method for the production of the ~~recombinant~~ antibody ~~product~~ according to claim 1 ~~or 2~~, characterized by the steps of:

- a) obtaining mRNA from freshly subcloned hybridoma cells of ATCC deposit number CRL 8001 and transcription into cDNA,
- b) amplifying the cDNA coding for the variable domains of the light and heavy chains by means of PCR,
- c) cloning of the cDNA obtained in b) into a vector adapted for site-specific mutagenesis ~~as well as introduction of~~,
- d) introducing a mutation to the cDNA in said position H100A of the V_H domain, wherein said position H100A is according to the Kabat numbering system, wherein said mutation is the substitution of a cysteine with a polar amino acid at position H100A of the V_H domain according to the Kabat numbering system, and
- d) e) inserting the mutated cDNA obtained in c) in an expression vector and expression in a suitable expression system.

5. (previously amended) ~~The method according to claim 4, wherein the amplifying of step b) uses primers having the nucleotide sequences depicted by SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10 and SEQ ID NO:11.~~

N/E Duplicate
6. (previously amended) The method according to claim 4, wherein the vector used in step c) is pCR-Skript SK(+).

7. (previously amended) The method according to claim 4, wherein said cloning

uses a primer comprising the sequence depicted by SEQ ID NO: 7.

Claim 8 (cancelled).

9. (previously amended) The method according to claim 4, wherein the expression takes place in XL1-Blue *E. coli* cells.

12. (previously amended) The method according to claim 5, wherein the vector used in step c) is pCR-Skript SK(+).

13. (previously amended) The method according to claim 5, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

14. (previously amended) The method according to claim 6, wherein said cloning uses a primer comprising the sequence depicted by SEQ ID NO: 7.

Claims 15-18 (cancelled).

19. (previously amended) The method according to claim 5, wherein the expression takes place in XL1-Blue *E. coli* cells.

20. (previously amended) The method according to claim 6, wherein the expression takes place in XL1-Blue *E. coli* cells.

21. (previously amended) The method according to claim 7, wherein the expression takes place in XL1-Blue *E. coli* cells.

Claim 22 (cancelled).

23. (previously amended) A peptide comprising the amino acid sequence depicted by SEQ ID NO:2.

24. (previously amended) An antibody comprising the peptide according to Claim 23.

25. (previously amended) A single-chain antibody comprising the peptide according to Claim 23.

26. (previously amended) A bispecific antibody comprising the peptide according to Claim 23.

Claim 27 (cancelled).[✓]

28. (new) The antibody of claim 1, wherein said antibody is a monoclonal antibody.

F⁶ 29. (re-presented former dependent claim 2) An antibody, comprising the V_H domain of the antibody produced by the hybridoma of ATCC deposit number CRL 8001, wherein the cysteine at position H100A of said V_H domain is substituted with a serine, wherein said position H100A is according to the Kabat numbering system, wherein said antibody comprises the amino acid sequence depicted by SEQ ID NO:2.
